ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC).
Authors
Coleman, ROza, A
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, J
Clamp, Andrew R
Scambia, G
Leary, A
Holloway, R
O’Malley, D
Cameron, T
Maloney, L
Goble, S
Lin, K
Sun, J
Giordano, H
Ledermann, J
Affiliation
The University of Texas MD Anderson Cancer Center, HoustonIssue Date
2018-08-01
Metadata
Show full item recordCitation
ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). 2018, 24(15_Suppl): 30-31 Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1557-3265.OVCA17-PR06Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1557-3265.OVCA17-PR06